These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 39133123)

  • 1. Clinical pharmacodynamics of obeldesivir versus remdesivir.
    Faghihi I; Yan VC
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0096924. PubMed ID: 39133123
    [No Abstract]   [Full Text] [Related]  

  • 2. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
    Sreekanth Reddy O; Lai WF
    Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remdesivir treatment does not reduce viral titers in patients with COVID-19.
    Faghihi I; Yan VC
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0085624. PubMed ID: 39023261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
    Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
    Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
    Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ
    EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice.
    Carlin AF; Beadle JR; Ardanuy J; Clark AE; Rhodes V; Garretson AF; Murphy JA; Valiaeva N; Schooley RT; Frieman MB; Hostetler KY
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0103924. PubMed ID: 39240093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
    Liang C; Tian L; Liu Y; Hui N; Qiao G; Li H; Shi Z; Tang Y; Zhang D; Xie X; Zhao X
    Eur J Med Chem; 2020 Sep; 201():112527. PubMed ID: 32563812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir: a pendulum in a pandemic.
    Schwartz IS; Heil EL; McCreary EK
    BMJ; 2020 Nov; 371():m4560. PubMed ID: 33234523
    [No Abstract]   [Full Text] [Related]  

  • 9. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC
    J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154
    [No Abstract]   [Full Text] [Related]  

  • 10. Remdesivir: A giant step, or a tiptoe?
    Dickinson GM
    Clin Dermatol; 2020; 38(6):773-774. PubMed ID: 32405143
    [No Abstract]   [Full Text] [Related]  

  • 11. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
    Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
    Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
    Moirangthem DS; Surbala L
    Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
    Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
    Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad-Spectrum
    Lo MK; Shrivastava-Ranjan P; Chatterjee P; Flint M; Beadle JR; Valiaeva N; Murphy J; Schooley RT; Hostetler KY; Montgomery JM; Spiropoulou CF
    Microbiol Spectr; 2021 Dec; 9(3):e0153721. PubMed ID: 34817209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Barone F; Giacomelli A; Casalini G; Corbellino M; Lai A; Gori A; Antinori S
    J Antimicrob Chemother; 2024 Sep; 79(9):2400-2402. PubMed ID: 39073825
    [No Abstract]   [Full Text] [Related]  

  • 16. Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment.
    Chatterjee S
    Drug Res (Stuttg); 2021 Mar; 71(3):138-148. PubMed ID: 33124007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
    Shahrbaf MA; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
    Hashemian SM; Farhadi T; Velayati AA
    Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2020; 14(4):641-648. PubMed ID: 32428865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the molecular structure of Remdesivir for the treatment of Covid-19.
    Sheikholeslami SM; Jahanbani A; Shao Z
    Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.